Dear, Richard http://orcid.org/0000-0002-1670-6767
Wagstyl, Konrad
Seidlitz, Jakob http://orcid.org/0000-0002-8164-7476
Markello, Ross D. http://orcid.org/0000-0003-1057-1336
Arnatkevičiūtė, Aurina http://orcid.org/0000-0003-4098-7084
Anderson, Kevin M.
Bethlehem, Richard A. I. http://orcid.org/0000-0002-0714-0685
Raznahan, Armin http://orcid.org/0000-0002-5622-1190
Bullmore, Edward T.
Vértes, Petra E. http://orcid.org/0000-0002-0992-3210
,
Article History
Received: 1 October 2022
Accepted: 18 March 2024
First Online: 22 April 2024
Competing interests
: K.M.A. is an employee of Neumora Therapeutics. R.D.M. is an employee of Octave Biosciences. E.T.B. has consulted for Boehringer Ingelheim, SR One, GlaxoSmithKline, Sosei Heptares and Monument Therapeutics. All other authors have no disclosures to make.